A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.
about
Optimal combination of antiangiogenic therapy for hepatocellular carcinomaImplications of biomarkers in human hepatocellular carcinoma pathogenesis and therapyStructural Insights into the Functions of TBK1 in Innate Antimicrobial ImmunityPhase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinomaFGFR1 amplifications in squamous cell carcinomas of the lung: diagnostic and therapeutic implications.Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.HCC and angiogenesis: possible targets and future directionsA phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenibHepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular CarcinomaHemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies.Antiangiogenic therapies for advanced hepatocellular carcinoma.Targeted therapies for hepatocellular carcinoma.Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancerClinical trials in hepatocellular carcinoma: an update.Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy.Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.The molecular pathogenesis and clinical implications of hepatocellular carcinoma.Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma.FGF receptor inhibitors: role in cancer therapy.Targeted therapy of hepatocellular carcinoma: present and future.Management of hepatocellular carcinoma: beyond sorafenib.Potential dual role of KGF/KGFR as a target option in novel therapeutic strategies for the treatment of cancers and mucosal damages.Impact of restricting access to high-cost medications for hepatocellular carcinoma.Pathways and targets in hepatocellular carcinoma.New agents on the horizon in hepatocellular carcinoma.Molecular targeted therapy for hepatocellular carcinoma: current and future.Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety.Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy.Fibroblast growth factor signaling in liver carcinogenesis.New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions.Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.Targeting the tumor stroma in hepatocellular carcinoma.Multi-kinase inhibitors, AURKs and cancer.Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma.Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma.Polymorphisms of FGFR1 in HBV-related hepatocellular carcinoma.Predicting responsiveness to sorafenib: can the determination of FGF3/FGF4 amplifications enrich for clinical benefit?Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy.Anti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future perspectives.Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: randomized phase II multicenter trial.
P2860
Q26799458-98F8475E-C48D-4336-A4AD-C04F5C216FD8Q27005850-696E2405-F7BE-42FA-ADCD-AC3534D86014Q27678533-5E4E4248-57D3-4C26-8A43-27D677108DC3Q34217671-8E691D20-ED89-46AA-93DB-B934F346EA67Q35206634-A9ACB174-98BE-4B50-BDF0-C524BB360A8AQ35501246-47F4F2CE-F519-44EE-9B97-DC1126D2261DQ35698574-A3E34FE8-F3E9-42FC-8411-D813CC9716A3Q36223538-1D4A0222-3A01-443A-B7BB-2AD37D6D302BQ36382891-9DBF1A06-3AC0-42D4-9225-B4520BA8C68DQ36644408-660F17FD-CD74-4D51-B81F-53D4F921DB2DQ36804518-10B9EA04-F927-4572-8977-022FF243096CQ36928888-CE054766-9C05-4EDB-88FA-43ACCA43A2E2Q37235534-36BD5453-4722-4E89-8FC5-4E2E8C353B09Q37435638-CA0ACF78-EE46-4868-B878-C38F74F70011Q37635310-C395D7B4-0E0A-4D38-99C0-6CE197E5C697Q37914633-ADAB9AF2-F2B7-47E6-B828-A34D23656057Q37970351-0B8D4A74-BE16-4968-A379-8D9DC7CB6876Q37978104-9BF20C0A-04DB-4F03-B522-66034F7A32B5Q37981986-45A17A0E-FB9C-4F32-982A-45FEC2C73734Q37988604-4345C0CA-0C17-4A82-BF9C-E1FC6290D572Q37995523-0446391F-AF55-4923-A926-E569C3189CF9Q37996468-B473F515-EB90-4EAA-9BB0-C2AC30495834Q38042711-A36D051D-414B-4CF7-AF81-7712FC562BBBQ38062022-708A43BF-FDB0-44B3-9F40-78315F428BDDQ38074429-35153291-FC97-411B-90C6-0049AF729BC4Q38151670-DD05FB12-3F1B-4D5C-854B-C8541C2AFF18Q38160838-81C0209F-444D-450A-9F23-1336EE4F7D18Q38184582-F782C0D4-CBF8-4729-BCBD-3855881452D2Q38203285-5120B81F-7B0C-4631-8842-0A983F4D10EAQ38282800-24897080-197A-4DC9-9301-86D2DD1EB8C2Q38354294-46D102DE-E6CB-4651-8000-53F2221915A0Q38366586-E1862ADE-1C83-4403-83AA-7358F2D4F257Q38796360-8020E734-ED44-4C7C-B8D9-2CDDEBD2CCC3Q38923517-AE1BFA99-E6B5-46C3-9A51-6F66F2210CA8Q40707153-9DCC0D44-5B44-4896-95B5-575D0483B529Q41166121-46EED969-4AFD-40C3-B610-AE57F6C7BFA1Q41761530-57B747CF-D30E-4AA2-89C9-EDE9BF4429B9Q42053469-31CDE880-786C-428B-B41D-53C320E9D3D0Q42871162-5DEB8F27-9F70-4C30-A77A-D466AE3B0BB5Q53287385-CE85DE08-9F15-4EEA-AC0B-3AC6C5C548FF
P2860
A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
A phase I/II trial of the oral ...... nced hepatocellular carcinoma.
@en
A phase I/II trial of the oral ...... nced hepatocellular carcinoma.
@nl
type
label
A phase I/II trial of the oral ...... nced hepatocellular carcinoma.
@en
A phase I/II trial of the oral ...... nced hepatocellular carcinoma.
@nl
prefLabel
A phase I/II trial of the oral ...... nced hepatocellular carcinoma.
@en
A phase I/II trial of the oral ...... nced hepatocellular carcinoma.
@nl
P2093
P2860
P921
P1476
A phase I/II trial of the oral ...... nced hepatocellular carcinoma.
@en
P2093
Chigusa Morizane
Fumihiko Kanai
Haruhiko Yoshida
Hitoshi Arioka
Kazumi Tagawa
Makoto Taniguchi
Masafumi Ikeda
Masao Omata
Shinpei Sato
Shuichiro Shiina
P2860
P2888
P304
P356
10.1007/S00280-010-1320-2
P577
2011-02-01T00:00:00Z